Mozambique Health Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP
Condition:   HIV Infections Interventions:   Biological: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48);   Biological: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48);   Biological: Vaccine Group C: Saline placebo (weeks 0,4,24,48);   Drug: Control PrEP:TDF /FTC once daily (weeks 0-26);   Drug: Experimental PrEP:TAF/FTC once daily (weeks 0-26) Sponsors:   MRC/UVRI Uganda Research Unit on Aids;   Imperial College London;   University College, London;   International AIDS Vaccine Initiative;   EuroVacc Foundation;   Med...
Source: ClinicalTrials.gov - August 26, 2019 Category: Research Source Type: clinical trials